3,024 results on '"Dinardo, Courtney D."'
Search Results
2. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
3. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms
4. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses
5. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
6. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
7. Current status and research directions in acute myeloid leukemia
8. Author Correction: Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress
9. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)
10. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression
11. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
12. Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine
13. Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations
14. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
15. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
16. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm
17. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia
18. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials
19. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
20. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
21. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
22. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
23. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
24. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
25. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
26. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
27. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
28. Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress
29. How I treat acute myeloid leukemia with differentiation therapy
30. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia
31. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
32. Hematopoiesis under telomere attrition at the single-cell resolution
33. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
34. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
35. Acute myeloid leukaemia
36. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
37. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
38. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies
39. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
40. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
41. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
42. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
43. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
44. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
45. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
46. Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
47. The impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
48. The spectrum of hematologic neoplasms in patients with Li‐Fraumeni syndrome.
49. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience.
50. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.